Adaptive 2025 Q3 Earnings Surges to Profitability with 129.7% Net Income Increase

Adaptive Biotechnologies (ADPT) delivered a standout Q3 2025 performance, exceeding revenue estimates by 38.15% and reporting a net income turnaround of 129.7% year-over-year. , signaling improved operational discipline. CEO highlighted MRD’s profitability milestones and strategic focus on scaling EMR integrations and immune medicine programs.

Revenue

, . The MRD segment led growth with $56.79 million in revenue, driven by 38% year-over-year clonoSEQ test volume expansion and NCCN guideline updates. Service revenue contributed $50.29 million, . , supported by $33.74 million in collaboration revenue and $3.44 million in service revenue.

Earnings/Net Income

Adaptive returned to profitability with net income of $9.54 million in Q3 2025, . , . , underscoring its operational turnaround.

Post-Earnings Price Action Review

, 2025, . , reflecting strong investor confidence in the company’s profitability milestones and revised guidance. , with bullish sentiment tied to MRD’s scalable growth and pharma partnership potential.

CEO Commentary

, driven by disciplined execution and clonoSEQ adoption. , . Robins expressed optimism about 2026 momentum, stressing long-term value creation through R&D efficiency and operational execution.

Guidance

, citing stronger clinical performance and milestone revenue. . , reinforcing confidence in sustained growth.

Additional News

, . , boosting clonoSEQ adoption. Additionally, , reflecting expanded partnerships in immune medicine.

, . . With a Zacks Rank #3 (Hold), investors await further clarity on long-term innovation and market expansion.